(NASDAQ: GMAB) Genmab A's forecast annual revenue growth rate of 16.9% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.77%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Genmab A's revenue in 2025 is $3,148,620,000.On average, 7 Wall Street analysts forecast GMAB's revenue for 2025 to be $237,678,093,312, with the lowest GMAB revenue forecast at $230,895,987,072, and the highest GMAB revenue forecast at $247,445,298,072. On average, 7 Wall Street analysts forecast GMAB's revenue for 2026 to be $286,723,697,588, with the lowest GMAB revenue forecast at $266,973,485,052, and the highest GMAB revenue forecast at $304,692,674,683.
In 2027, GMAB is forecast to generate $332,153,542,201 in revenue, with the lowest revenue forecast at $305,963,661,768 and the highest revenue forecast at $348,991,870,368.